 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...9596979899100101102103104105...858859» |
- | Ibrance (palbociclib) / Pfizer
Journal, Metastases: Palbociclib: Safe and Effective in an 85-Year-Old Female with Metastatic Bilateral Breast Cancer. (Pubmed Central) - Feb 12, 2024
Null.
- ||||| camizestrant (AZD9833) / AstraZeneca
Enrollment closed: SERENA-4: A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (clinicaltrials.gov) - Feb 11, 2024
P3, N=1370, Active, not recruiting, Sponsor: AstraZeneca
Null. Recruiting --> Active, not recruiting
- | ivabradine / Generic mfg., trimetazidine / Generic mfg.
Journal: Painful left bundle branch block (Pubmed Central) - Feb 11, 2024
Recruiting --> Active, not recruiting No abstract available
- | Tepezza (teprotumumab) / Roche, Amgen
Journal, HEOR: Bridging and Validation of the Specific Graves' Ophthalmopathy Quality of Life (GO-QOL) Questionnaire with Health State Utility Values. (Pubmed Central) - Feb 11, 2024
Patients with moderate-severe active TED health states demonstrate increasing TED severity associated with declining utility values and worsening GO-QOL scores. These results indicate GO-QOL scores can be used to bridge to health state utility scores for benefit quantification.
- || Cimzia (certolizumab pegol) / Astellas, UCB
PK/PD data, Review, Journal: Summary of certolizumab pegol in psoriasis including structural features, pharmacokinetics (Pubmed Central) - Feb 10, 2024
Among the five TNF-? inhibitors available for psoriasis, namely infliximab, adalimumab, etanercept, golimumab
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma. (Pubmed Central) - Feb 10, 2024
At baseline, mucus plug scores correlated positively with levels of inflammatory biomarkers and negatively with lung function measures. Patients treated with tezepelumab had resolution of more mucus plugs than patients taking placebo.
- | Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
Journal: Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer. (Pubmed Central) - Feb 10, 2024
The effectiveness of cyclin-dependent kinase 4/6 inhibitors is unlikely to be affected by concomitant PPI use. Future prospective pharmacokinetic studies are warranted.
- | Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer, Jeselhy (pimitespib) / Otsuka
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer. (Pubmed Central) - Feb 10, 2024
We identified molecular features associated with the response to the REGONIVO and TASNIVO, particularly those related to tumor microenvironmental factors. These findings are likely to contribute to the development of biomarkers to predict treatment efficacy for MSS/pMMR CRC and future immunotherapy combinations for treatment.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Novel Therapeutic Targets on the Horizon: An Analysis of Clinical Trials on Therapies for Bone Metastasis in Prostate Cancer. (Pubmed Central) - Feb 10, 2024
Therefore, managing patients with prostate cancer that has spread to the bones often involves using bone-targeted medications like bisphosphonates and denosumab to enhance bone structure and minimize skeletal complications...The analysis included details such as patient recruitment, prior palliative therapies, baseline characteristics, follow-up, and outcome reporting. The goal was to highlight the advancements and trends in bone metastasis research in prostate cancer over the past decade, with the aim of developing strategies to prevent and treat bone metastases and improve the quality of life and survival rates for prostate cancer patients.
- || Opdivo (nivolumab) / Ono Pharma, BMS, Stivarga (regorafenib) / Bayer
Biomarker, P1 data, Journal, Mismatch repair, PD(L)-1 Biomarker, Metastases: Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer. (Pubmed Central) - Feb 10, 2024
This study suggests that pretreatment albumin, MIP-1?, non-liver metastatic disease and Treg infiltration may be potential predictive biomarkers of regorafenib/nivolumab in pMMR colorectal cancer. Further studies are needed to confirm these findings.
- || Review, Journal: The New Therapeutic Frontiers in the Treatment of Eosinophilic Esophagitis: Biological Drugs. (Pubmed Central) - Feb 10, 2024
Despite the undeniable economic impact of biologic therapies, in the near future, there will be room for further reflection about the opportunity to prescribe biologic agents, not only as a last-line therapy in selected cases such as patients with comorbidities involving common pathways. Although recent findings are very encouraging, the road to permanent success in the treatment of EoE is still long, and further studies are needed to determine the long-term effects of mAbs and to discover new potential targets.
- | Lumakras (sotorasib) / Amgen
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker: Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRASG12C-Mutated Lung Adenocarcinoma. (Pubmed Central) - Feb 10, 2024
The findings indicate that these newly identified biomarkers are linked to the abnormal expression of PDL1 and have the potential to induce resistance through immunosuppression. These results highlight the need for further research and therapeutic intervention to address this issue effectively.
- | Solymbic (adalimumab biosimilar) / Amgen, Amjevita (adalimumab-atto) / Amgen, Daiichi Sankyo, Hyrimoz (adalimumab-adaz) / Sandoz
Retrospective data, Journal: Adalimumab Biosimilar in Pediatric Inflammatory Bowel Disease: A Retrospective Study from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD). (Pubmed Central) - Feb 10, 2024
This is the first real-world study that particularly addresses the use of ADL-BioS in pediatric IBD. With high rates of treatment persistence and a low frequency of non-serious side effects, ADL-BioS seems to be effective.
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Comparison of Incidence or Recurrence of Anterior Uveitis in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor Inhibitors. (Pubmed Central) - Feb 10, 2024
In the short-term period following TNFi therapy, etanercept induced new-onset AU more frequently than adalimumab in patients with AS. Adalimumab recipients experienced fewer AU recurrences during the subsequent long-term period compared to other TNFi recipients.
- | Repatha (evolocumab) / Amgen, Astellas
Retrospective data, Journal: Safety and Efficacy of PCSK9 Inhibitors in Patients with Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Grafts: A Comparative Retrospective Analysis. (Pubmed Central) - Feb 10, 2024
Evolocumab initiated "as soon as possible" in ACS patients submitted to CABG with high-intensity statin therapy and Ezetimibe was well tolerated and resulted in a substantial and significant reduction in LDL-C levels at discharge, 1 month, and 3 months. This result is associated with a reduction but without a statistical difference between groups.
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Journal: Early Impact of Mobilization Process on Cardiac Function and Size in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. (Pubmed Central) - Feb 10, 2024
This result is associated with a reduction but without a statistical difference between groups. All patients underwent hematopoietic stem cell mobilization with chemotherapy and filgrastim at 10
- || Review, Journal: Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review. (Pubmed Central) - Feb 9, 2024
Recent studies have recommended JAK and TNF inhibitors, especially oral tofacitinib and adalimumab, as a new modality or adjuvant therapy to previous medications for primary CA. Nonetheless, monitoring AEs on a regular basis is suggested, and further extensive studies are required before definitive recommendations.
- | Journal: Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database. (Pubmed Central) - Feb 9, 2024
More reports of pericarditis were detected with AS patients on bDMARDs than with other drugs in the overall database. Further studies are warranted to investigate the underlying mechanisms and identify patient-related susceptibility factors, thus supporting timely diagnosis and safe(r) prescribing of bDMARDs.
- || Ibrance (palbociclib) / Pfizer
Clinical, Journal, Metastases: Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2- metastatic breast cancer: a prospective, monocentric study. (Pubmed Central) - Feb 9, 2024
ET and CT represent two possible therapeutic alternatives for patients progressing on CDK4/6i plus ET. The choice is based on clinical parameters, with a potential preference for ET.
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Enrollment open: Romosozumab for Patients with Multiple Myeloma with Skeletal Events on Zoledronic Acid: A Pilot Study (EUDRACT) - Feb 8, 2024
P2, N=12, Recruiting, Sponsor: St Vincent's Hospital, Sydney
The choice is based on clinical parameters, with a potential preference for ET. Not yet recruiting --> Recruiting
- | omecamtiv mecarbil (AMG 423) / Amgen, Servier
Journal: The structural OFF and ON states of myosin can be decoupled from the biochemical super- and disordered-relaxed states. (Pubmed Central) - Feb 8, 2024
In this study, we use X-ray diffraction and ATP turnover assays to track the structural and biochemical transitions of myosin heads, respectively, induced with either omecamtiv mecarbil (OM) or piperine in relaxed porcine myocardium...Our results show that biochemically defined SRX and DRX can be decoupled from structurally defined OFF and ON states. In summary, while SRX/DRX and OFF/ON transitions can be correlated in some cases, these two phenomena are measured using different approaches, reflect different properties of the thick filament, and should be investigated and interpreted separately.
- | Vectibix (panitumumab) / Amgen
Journal, Metastases: Editorial: Optimizing the first-line treatment for metastatic colorectal cancer. (Pubmed Central) - Feb 8, 2024
In summary, while SRX/DRX and OFF/ON transitions can be correlated in some cases, these two phenomena are measured using different approaches, reflect different properties of the thick filament, and should be investigated and interpreted separately. No abstract available
- Enbrel (etanercept) / Pfizer, Amgen
Predicting Response to Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis Using an Extended Set of Clinical and Laboratory Variables Remains Suboptimal () - Feb 8, 2024 - Abstract #CRAAHPA2024CRA_AHPA_192;
Despite an extended set of clinical and laboratory predictors, we found only modest discrimination between anti-TNF responders and non-responders in RA, similar to previously reported models. In an era with multiplying drugs available to treat RA, our study highlights the need for further research to predict the most appropriate treatments for individual patients, which holds the potential for improved outcomes and cost savings.
- Tavneos (avacopan) / Kissei, Amgen, Otsuka
Workshop 1A - Navigating the Future: Updates in ANCA Associated Vasculitis Management through Cases and Collaboration () - Feb 8, 2024 - Abstract #CRAAHPA2024CRA_AHPA_19;
Topics covered will include the less is more paradigm shift in prednisone prescribing, adjuvant therapies in ANCA associated vasculitis (such as avacopan and plasmapheresis), how to select a maintenance agent, and how to decide on the duration of maintenance therapy. Attendees will also gain insight from the nephrology perspective so that they have the skills to collaborate with nephrology on these complex patients.CanMEDS rolesMedical ExpertCollaboratorHealth AdvocateScholarProfessional
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Clinical application of bone turnover markers in osteoporosis. (Pubmed Central) - Feb 8, 2024
This review describes how BTM can be used for treatment monitoring, including monitoring during discontinuation of alendronate and denosumab therapy. In addition, sources of errors and pitfalls when using BTM monitoring will be described.
- | ivabradine / Generic mfg.
Preclinical, Journal: The role of HCN channels on the effects of T-type calcium channels and GABA receptors in the absence epilepsy model of WAG/Rij rats. (Pubmed Central) - Feb 8, 2024
In this study we used ivabradine (IVA), a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker, to identify its effect on spike-wave discharges (SWDs); and aimed to determine the role of IVA on the effects of T-type calcium channel blocker NNC 55-0396, GABAA receptor agonist muscimol and antagonist bicuculline in male WAG/Rij rats...Subacute administration of IVA reduced the antiepileptic activity of NNC, while the proepileptic activity of muscimol and the antiepileptic activity of bicuculline were abolished. It might be suggested that subacute IVA administration reduces absence seizures by changing the HCN channel expressions in WAG/Rij rats, and this affects the T-type calcium channels and GABA receptors.
- | Ibrance (palbociclib) / Pfizer
Journal: Design, development, and evaluation of CDK-4/6 inhibitor loaded 4-carboxy phenyl boronic acid conjugated pH-sensitive chitosan lecithin nanoparticles in the management of breast cancer. (Pubmed Central) - Feb 8, 2024
Our main aim to design and develop a novel 4-carboxy phenyl boronic acid (4-CPBA) conjugated Palbociclib (PALB) loaded pH-sensitive chitosan lipid nanoparticles (PPCL) to enhance the anti-cancer efficacy of the PALB in in-vitro cell line studies by loading into 4-CPBA conjugated chitosan lipid nanoparticles...PPCL caused extensive mitochondrial depolarization, enhanced ROS generation, apoptosis (DAPI nuclear staining, acridine orange/ ethidium bromide dual staining), and reduced % cell migration than pure PALB. It was concluded that the hybrid lipid-polymer nanoparticles provides an optimistic approach for the treatment of breast cancer.
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor (clinicaltrials.gov) - Feb 8, 2024
P3, N=416, Completed, Sponsor: St. Jude Children's Research Hospital
It was concluded that the hybrid lipid-polymer nanoparticles provides an optimistic approach for the treatment of breast cancer. Active, not recruiting --> Completed
- || rocatinlimab (KHK4083) / Amgen
Enrollment closed: A Study to Evaluate Rocatinlimab (AMG 451) in Healthy Chinese Participants (clinicaltrials.gov) - Feb 8, 2024
P1, N=20, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- | Stivarga (regorafenib) / Bayer
Trial completion: Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS (clinicaltrials.gov) - Feb 7, 2024
P=N/A, N=192, Completed, Sponsor: Istituto Oncologico Veneto IRCCS
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Lumakras (sotorasib) / Amgen
New P1 trial, Combination therapy, Metastases: Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov) - Feb 7, 2024
P1, N=15, Not yet recruiting, Sponsor: City of Hope Medical Center
- | Ibrance (palbociclib) / Pfizer
Journal, Tumor cell: Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2- breast tumor cells. (Pubmed Central) - Feb 7, 2024
Using trajectory inference approaches, we show how plasticity among cell cycle regulators gives rise to alternate cell cycle "paths" that allow individual tumor cells to escape palbociclib treatment. Understanding drivers of cell cycle plasticity, and how to eliminate resistant cell cycle paths, could lead to improved cancer therapies targeting fractionally resistant cells to improve patient outcomes.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Hypercalcemia: a practical review (Pubmed Central) - Feb 7, 2024
The chosen treatments and their speed of introduction depend mainly on the severity of hypercalcemia. They include intravenous rehydration, and antiresorptive agents such as bisphosphonates, denosumab or calcitonin.
- | Erbitux (cetuximab) / Eli Lilly, Vectibix (panitumumab) / Amgen, Stivarga (regorafenib) / Bayer
Enrollment closed, Enrollment change: REVERCE II: Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 7, 2024
P2, N=22, Active, not recruiting, Sponsor: Academic and Community Cancer Research United
They include intravenous rehydration, and antiresorptive agents such as bisphosphonates, denosumab or calcitonin. Recruiting --> Active, not recruiting | N=124 --> 22
- Detection of drug-induced interstitial lung disease caused by cancer treatment using electronic nose exhaled breath analysis (Congress Hall Foyer) - Feb 6, 2024 - Abstract #ELCC2024ELCC_580;
Recruiting --> Active, not recruiting | N=124 --> 22 Table: 246P Baseline Case n=20 Control n=20 Female 9 (45) 9 (45) Age 65.25
- Lumakras (sotorasib) / Amgen
SMARCA4 inactivation drives aggressiveness in STK11/KEAP1 co-mutant lung adenocarcinomas through the induction of TGF? signaling (Congress Hall Foyer) - Feb 6, 2024 - Abstract #ELCC2024ELCC_562;
These results provide mechanistic insight into the aggressiveness of SSK-mutant LUADs and nominates TGF? signaling as a therapeutic vulnerability in these.
- tarlatamab (AMG 757) / Amgen
Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774) (Congress Hall Foyer) - Feb 6, 2024 - Abstract #ELCC2024ELCC_547;
P3
Primary endpoint is progression-free survival (PFS) per blinded independent central review (RECIST 1.1) with OS as a key secondary endpoint. Additional secondary endpoints include investigator-assessed PFS, objective response, disease control, duration of response, time to progression, pharmacokinetics, tarlatamab immunogenicity, and safety/tolerability.
- Keytruda (pembrolizumab) / Merck (MSD), Lumakras (sotorasib) / Amgen
Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202) (Congress Hall Foyer) - Feb 6, 2024 - Abstract #ELCC2024ELCC_439;
P3
Exploratory endpoints include intra-cranial PFS per RANO-BM criteria. Approximately 750 patients are planned to be enrolled and recruitment began on November 18, 2023.
- Augtyro (repotrectinib) / BMS
Development of an online tool for the management of drug-drug interactions with the ROS1/TRK tyrosine kinase inhibitor repotrectinib (Congress Hall Foyer) - Feb 6, 2024 - Abstract #ELCC2024ELCC_378;
Conclusions Repotrectinib may be involved in a DDI with a number of widely-used antithrombotic agents, including all directly-acting oral anticoagulants (DOACs). An online tool can guide clinicians to manage DDIs between repotrectinib and relevant co-medications.
- tarlatamab (AMG 757) / Amgen
Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity (Forum Hall) - Feb 6, 2024 - Abstract #ELCC2024ELCC_323;
P1
100 mg D1/D8 eIV, extended IV; NE, not estimable Conclusions In longer follow-up of DeLLphi-300, tarlatamab demonstrated durable responses and unprecedented survival outcomes in previously treated SCLC. While limited to analyses of treated, stable brain metastases, CNS tumor shrinkage following tarlatamab therapy and long after RT supports further study of intracranial efficacy of tarlatamab.
- | Rinvoq (upadacitinib) / AbbVie
Journal: A Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib. (Pubmed Central) - Feb 6, 2024
J Drugs Dermatol. 2024;23(2): doi:10.36849/JDD.7645.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Retrospective data, Journal: Using Denosumab as a Nonsurgical Management of Aneurysmal Bone Cysts in the Pelvis. (Pubmed Central) - Feb 6, 2024
Denosumab may provide a reliable option in the nonsurgical treatment of ABCs of pelvic origin with expected lower morbidity than the surgical solution and tolerable complications. Further studies on the safety profile and long-term effects of denosumab especially in skeletally immature patients are required.
- | Stivarga (regorafenib) / Bayer
Journal: Two Cases of the Significant Liver Damage by Regorafenib (Pubmed Central) - Feb 6, 2024
The liver enzyme decreased afterwards. It may be easy to make the liver damage by regorafenib serious, and attention is necessary.
- | Journal, Metastases: A Case of Advanced Recurrent Rectal Cancer Successfully Treated by Rechallenge Therapy with an Anti-Epidermal Growth Factor Receptor(EGFR)Drug (Pubmed Central) - Feb 6, 2024
Based on the findings of molecular and pathological examinations(RAS: wild type; BRAF: wild type; MSI: negative; HER2: negative), the following chemotherapy regimens were administered: first-line, FOLFIRI plus panitumumab(PANI); second-line, mFOLFOX6; third-line, trifluridine/tipiracil; fourth- line, regorafenib...Therefore, rechallenge therapy with anti-epidermal growth factor receptor(EGFR)drugs, cetuximab(CET)and irinotecan(IRI), was administered 13 months after the final course of FOLFIRI plus PANI treatment. After 4 courses of CET plus IRI, the size of the 2 metastatic tumors markedly decreased and his tumor marker levels normalized.
- | 5-fluorouracil / Generic mfg.
Journal: A Case of Sigmoid Rectal Cancer with a Vesicoconstrictor Fistula Curatively Resected after Neoadjuvant Chemotherapy (Pubmed Central) - Feb 6, 2024
The patient underwent robotic-assisted low anterior resection of the rectum and partial cystectomy, which yielded pathological radical treatment. We report a case of sigmoid colon cancer with a colovesical fistula complicated by bladder invasion, in which preoperative chemotherapy was effective and total cystectomy was avoided, allowing bladder preservation.
- | Vectibix (panitumumab) / Amgen
Journal: A Case of Robot-Assisted Abdominoperineal Resection Alongside En Bloc Prostatectomy and Vesico-Urethral Anastomosis for Local Recurrence (Pubmed Central) - Feb 6, 2024
He exhibited a good postoperative course and was discharged on the 12th postoperative day. After 7 months of surgery, no recurrence was observe; and urinary incontinence seen immediately after surgery gradually improved.
- | 5-fluorouracil / Generic mfg.
Journal, Metastases: A Case of Locally Advanced Giant Sigmoid Colon Cancer Successfully Treated with Neoadjuvant Chemotherapy (Pubmed Central) - Feb 6, 2024
She received neoadjuvant chemotherapy with 4 courses of mFOLFOX6, in addition to panitumumab...Adjuvant chemotherapy was not administered owing to the patient's refusal. She remained recurrence-free for 3 years of postoperative follow up.
- | Vectibix (panitumumab) / Amgen
Journal: Treatment Strategy for Familial Adenomatous Polyposis Presenting with Obstructive Colorectal Cancer and Concurrent Liver Metastasis (Pubmed Central) - Feb 6, 2024
We decided to first create a loop stoma at the transverse colon for the obstructive rectal cancer, and then administer neoadjuvant chemotherapy(mFOLFOX6 plus panitumumab)...As for clinicopathological findings, round 50 polyps were identified in the colon and rectum, and rectal cancer invaded into the muscularis propria. Finally, the patient was diagnosed as a clinically attenuated FAP with ypT2 rectal cancer.
- ||| 5-fluorouracil / Generic mfg.
Journal, Adverse events: A Case of Descending Colon Cancer with Distant Metastasis That Was Controlled Severe Side Effects of Chemotherapy and Achieved Long-Term CR (Pubmed Central) - Feb 6, 2024
After the surgery mFOLFOX6 plus panitumumab was introduced...The chemotherapy was discontinued 48 months after administration. He is alive without recurrence for 32 months after completion of treatment.
- | 5-fluorouracil / Generic mfg.
Journal: Considering Recurrence Prevention Regimen for Colorectal Cancer Patients with Hyperammonemia Caused by Chemotherapy Containing 5-Fluorouracil (Pubmed Central) - Feb 6, 2024
Because of RAS/BRAF wild type, we started the mFOLFOX6 plus panitumumab (Pmab)...After that, the chemotherapy was changed to 5-FU 80% FOLFIRI plus bevacizumab, but hyperammonemia recurred...In this case, muscle weakness due to sarcopenia was considered to be one of the causes. We believe that oral drugs containing FTD/TPI can be used relatively safely without causing hyperammonemia.